Please login to the form below
Hodgkin lymphoma
This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
AZ nabs US approval for new leukaemia drug Lumoxiti
Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Latest news
-
Affimed rockets on $5bn-plus Roche immuno-oncology deal
which targets CD30 and is in a phase 2a Hodgkin lymphoma study, and AFM24 which targets CD19 and is in phase I for non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukaemia
-
It’s a no for Yescarta, says NICE on heels of EU approval
It’s disappointing that patients with non-Hodgkin lymphoma who have exhausted all other treatment options will not be able to access CAR T cell therapy – a brand new type of ... Cell therapy is a new and advanced technology and, as NICE have
-
FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo
FDA clears Kyowa Kirin’ s skin lymphoma therapy Poteligeo. Becomes the first drug approved to treat Sézary syndrome. ... Both MF and SS are a rare form of non-Hodgkin’s lymphoma (NHL) collectively known as cutaneous T-cell lymphomas (CTCL), and are
-
China’s BeiGene raises $903m from Hong Kong IPO
In addition to PD-1 inhibitor tislelizumab, which will be filed initially in relapsed/refractory classical Hodgkin’s lymphoma and is also in late-stage trials for non-small cell lung
-
Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE
Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE. ... or refractory classical Hodgkin lymphoma.
More from news
Approximately 5 fully matching, plus 191 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
-
Deal Watch June 2016
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Pharma deals in April 2015
Under the terms of the deal, Celgene has the rights to develop the product for non-Hodgkin lymphoma (NHL), myelodysplastic syndromes and multiple myeloma. ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL)
-
Medius Deal Watch table for February 2015
CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century Hodgkin’ ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Systematic Review Lead- London
-
Negotiable
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
-
Associate Scientific Director
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Account Manager
-
Negotiable
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- Moving annual total (MAT)
- AZ prepares to file COPD triple, taking on rival GSK
- J&J files ‘breakthrough’ bladder cancer drug in US
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Teva wins FDA OK for crucial migraine drug
- NHS wins legal fight with pharma over off-label Avastin
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
